Specific inhibition of DNMT1/CFP1 reduces cancer phenotypes and enhances chemotherapy effectiveness - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Epigenomics Année : 2014

Specific inhibition of DNMT1/CFP1 reduces cancer phenotypes and enhances chemotherapy effectiveness

Résumé

Aim: DNA methylation is a fundamental biologic process of genomes and is a candidate for pharmacological manipulation that might have important therapeutic advantages. Thus, DNA methyltransferases (DNMTs) appear to be ideal targets for drug intervention. Materials & methods: To develop a new generation of DNMT inhibitor, we analyzed the ability of peptides to selectively inhibit certain DNMT1-incuding complexes. Results: Our study demonstrates that the disruption of DNMT1/CFP1-including complexes increases the efficiency of chemotherapeutic treatment on established tumors in mice. Conclusion: Our data opens a promising and innovative alternative to the development of DNMT inhibitors
Fichier non déposé

Dates et versions

inserm-02478615 , version 1 (14-02-2020)

Identifiants

Citer

Pierre-Francois Cartron, Mathilde Cheray, Arulraj Nadaradjane, Pascal Bonnet, Sylvain Routier, et al.. Specific inhibition of DNMT1/CFP1 reduces cancer phenotypes and enhances chemotherapy effectiveness. Epigenomics, 2014, 6 (3), pp.267-275. ⟨10.2217/epi.14.18⟩. ⟨inserm-02478615⟩
65 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More